Thyroid cancer is one of the few cancers most people encounter first as a word on an imaging report rather than as an illness they can feel. It is usually found because a lump was noticed in the neck, or because a scan done for another reason picked up a nodule nobody was looking for. That path to diagnosis shapes everything that follows, including why the outlook for most people is far better than the word cancer suggests. According to the National Cancer Institute, about 45,240 new cases are expected in the United States in 2026, with a five-year relative survival of 98.3 percent across all stages combined. This guide explains the types, the symptoms worth acting on, how diagnosis actually works, what survival figures mean, and how treatment has changed.
What thyroid cancer is
The thyroid is a butterfly-shaped gland at the base of the front of the neck. It produces the hormones that set the pace of your metabolism, and it contains two distinct cell populations. Follicular cells make thyroid hormone, and parafollicular cells, also called C cells, make calcitonin. Thyroid cancer arises when one of these cell types begins to grow abnormally, and which cell is involved determines the type of cancer, how it behaves, and how it is treated.
Most thyroid cancers grow slowly and stay confined to the gland or nearby lymph nodes for years. A minority behave aggressively. That wide range is why two people can both be told they have thyroid cancer and receive entirely different advice, and why comparing your situation to someone else’s is rarely helpful.
The five types of thyroid cancer
Thyroid cancers are grouped by the cell they come from and by how closely the tumour cells still resemble normal thyroid tissue. The first four in the table below arise from follicular cells; medullary cancer comes from C cells and behaves differently from all the others.
| Type | Share of cases | What characterises it |
|---|---|---|
| Papillary | Up to 90 percent | Slow growing, often spreads to neck lymph nodes, excellent outlook |
| Follicular | Up to 15 percent | Spreads through the bloodstream rather than lymph nodes when it spreads at all |
| Oncocytic (Hurthle cell) | 3 to 5 percent | A distinct follicular-cell tumour, less responsive to radioactive iodine |
| Medullary | Under 5 percent | Arises from C cells, produces calcitonin, can be inherited |
| Anaplastic | About 2 percent | Rare, grows rapidly, requires urgent specialist management |
Papillary and follicular cancers are grouped together as differentiated thyroid cancer, because their cells still behave enough like normal thyroid tissue to absorb iodine and produce thyroglobulin. That single property underpins both the treatment and the follow-up of the large majority of cases.
Symptoms of thyroid cancer
The most important thing to understand about thyroid cancer symptoms is that most early thyroid cancers cause none at all. The gland sits in front of the windpipe, and a small tumour has room to grow without pressing on anything. When signs do appear, the usual first one is a painless lump in the front of the neck that moves when you swallow.
- A lump or swelling in the front of the neck, felt or seen rather than painful
- Hoarseness or a change in the voice that persists for more than a few weeks
- Difficulty swallowing, or a sensation of food catching
- Difficulty breathing, or noisy breathing when lying flat
- Swollen lymph nodes at the side of the neck that do not settle
- Persistent neck or throat discomfort that is not explained by infection
Each of these has common, harmless explanations. Neck lumps are extremely frequent, and the overwhelming majority of thyroid nodules are benign. The reason these signs are listed is not that they usually mean cancer, but that they should be examined rather than watched indefinitely at home.
Are symptoms different in women?
The symptoms are the same in women and men. What differs is how often the diagnosis is made: thyroid cancer is diagnosed roughly three times more frequently in women, and the median age at diagnosis is 51. Oestrogen exposure is one of the hypotheses investigated for this difference, and higher rates of neck imaging in women may also contribute. There is no separate set of female symptoms, and the searches that suggest otherwise usually reflect this difference in incidence rather than in presentation.
When to seek care promptly
A neck lump that grows noticeably over weeks, a voice change that persists beyond three weeks, new difficulty breathing or swallowing, or a hard fixed lump that does not move with swallowing should be assessed promptly rather than at the next routine appointment. Rapid enlargement over days, particularly in an older adult, is the pattern that warrants urgent attention.
Risk factors and causes
Most people with thyroid cancer have no identifiable cause. The risk factors that are established include the following.
- Sex, since the diagnosis is substantially more common in women
- Exposure of the head or neck to radiation, particularly medical radiation received in childhood
- Inherited conditions, including familial medullary thyroid cancer, multiple endocrine neoplasia, Cowden syndrome, and familial adenomatous polyposis
- A family history of thyroid cancer in a first-degree relative
- Iodine intake at the extremes, either deficiency or long-term excess
Two things are worth stating plainly because they cause recurrent worry. Having an underactive or overactive thyroid does not itself cause thyroid cancer, and thyroid antibodies are a marker of autoimmune thyroid disease rather than of cancer; our guide covers what a positive result means in our anti-TPO antibody guide. The question of GLP-1 weight-loss and diabetes medications is addressed in the research section below.
How thyroid cancer is diagnosed
Diagnosis follows a sequence, and understanding it removes a great deal of unnecessary anxiety.
Why blood tests do not diagnose thyroid cancer
This is the single most common misunderstanding. Thyroid function tests measure how much hormone the gland is producing, not whether any cells within it are malignant. Most thyroid cancers are non-functioning, so hormone levels stay entirely normal. A thyroid-stimulating hormone test is still the first blood test ordered when a nodule is found, because the result decides the next step rather than the diagnosis, and you can read our TSH blood test guide. For the pattern the whole panel forms, consult our guide to normal thyroid levels, and for what that first result actually decides, see our thyroid nodule blood test guide.
There are two exceptions. Calcitonin is produced by C cells and is used in the assessment of medullary thyroid cancer, and our calcitonin blood test guide explains the thresholds involved. Thyroglobulin is produced by follicular cells and is used after treatment of differentiated cancer as a marker of residual or recurrent disease, not as a screening test in people who still have their thyroid.
Ultrasound, biopsy, and molecular testing
Neck ultrasound is the decisive imaging test. It describes a nodule’s size, composition, margins, and calcifications, and these features are scored to estimate the chance of malignancy and decide whether a biopsy is warranted. Many nodules are simply monitored.
When a biopsy is indicated, it is a fine-needle aspiration performed with a thin needle under ultrasound guidance, usually in a few minutes with local anaesthetic. The cells are classified on the Bethesda scale, from clearly benign through indeterminate categories to clearly malignant. Roughly a fifth of results land in the indeterminate middle, and this is where molecular testing of the biopsy sample has changed practice: analysing the genetic alterations present can distinguish nodules that need surgery from those that can safely be watched, sparing operations that would previously have been performed for diagnosis alone.
Thyroid cancer survival rate and staging
Survival statistics for thyroid cancer are unusual amongst cancers, and they are frequently misread. The SEER five-year relative survival across all stages is 98.3 percent, and for disease still confined to the thyroid it approaches 100 percent. Around 2,320 deaths are expected in the United States in 2026 against more than 45,000 diagnoses.
Three points make these numbers interpretable. First, a relative survival rate compares people with the diagnosis to people of the same age without it, so it isolates the effect of the cancer. Second, the figures are dominated by papillary cancer, which carries the best outlook; anaplastic cancer, at about 2 per cent of cases, has a very different prognosis and is not represented by the headline number. Third, thyroid cancer staging is the only common cancer staging system where age is a criterion: under 55, differentiated thyroid cancer is classified only as stage I or stage II even when it has spread, because outcomes in younger patients remain excellent.
Statistics describe groups of people diagnosed years ago and treated with the methods of that time. They do not predict what will happen to any individual, and your own outlook depends on the type, the stage, your age, and how the disease responds to treatment.
How thyroid cancer is treated
Treatment has moved steadily towards doing less where less is enough, a shift the 2025 American Thyroid Association guidelines describe explicitly.
Active surveillance
For very small, low-risk papillary cancers confined to the gland, monitoring with regular neck ultrasound is now an accepted first option rather than immediate surgery. The patient is followed rather than operated on, and surgery is performed only if the tumour grows or lymph nodes become involved. The evidence behind this is covered in the research section below.
Surgery, radioactive iodine, and systemic treatment
- Lobectomy removes one half of the thyroid and is increasingly preferred for small, low-risk tumours, often leaving enough gland to avoid lifelong hormone replacement
- Total thyroidectomy removes the whole gland and is used for larger or higher-risk tumours, and always requires daily thyroid hormone afterwards
- Radioactive iodine is given after surgery in selected cases: differentiated thyroid cells absorb iodine, so the radioactive form destroys remaining thyroid tissue whilst sparing the rest of the body. It is now used more selectively than it once was
- Thermal ablation techniques, which destroy a small tumour with heat delivered through a needle, have entered guidelines as an option in defined situations
- Targeted drugs are used for advanced disease that no longer responds to iodine, chosen according to the genetic alterations found in the tumour, such as RET or BRAF changes
- Conventional chemotherapy has a limited role, mainly in anaplastic disease, and external beam radiotherapy is used selectively
What follow-up looks like
After treatment of differentiated thyroid cancer, follow-up combines neck ultrasound with a thyroglobulin blood test, since thyroglobulin should be very low or undetectable once the gland has been removed. Thyroid hormone replacement is monitored with TSH and free T4, and our free T4 guide explains that second value. The parathyroid glands sit immediately behind the thyroid and can be bruised during surgery, so calcium is checked in the days afterwards; read our calcium blood test guide and, for the hormone that controls it, our PTH blood test guide. In medullary cancer, calcitonin takes the place of thyroglobulin as the marker followed over time.
Latest scientific advances
The last three years have been unusually active for thyroid cancer, and the direction of change is consistent: more precise selection of who needs intensive treatment, and less of it for everyone else. The summaries below are drawn from peer-reviewed literature and clinical guidelines. None of them replaces the advice of the team treating an individual patient.
The American Thyroid Association published revised management guidelines for adults with differentiated thyroid cancer in 2025, the first full update since 2015. The changes highlighted by the panel include an expanded role for molecular diagnostics, refined risk stratification, a greater emphasis on active surveillance and on lobectomy rather than total thyroidectomy, the inclusion of ablative procedures, and reduced-intensity surveillance for low-risk patients after treatment. For readers, the practical consequence is that advice given before 2025 may differ from advice given today, and that a second opinion framed around the current guidelines is a reasonable thing to ask for.
The evidence base for active surveillance has matured considerably. A 2023 report of 30 years of experience at a single Japanese centre compared 3,222 adults with low-risk papillary microcarcinoma who were monitored against 2,424 who had immediate surgery. In the surveillance group, 3.8 per cent had tumour enlargement of at least 3 millimetres, with 10-year and 20-year enlargement rates of 4.7 and 6.6 per cent, and new lymph node involvement occurred in 0.8 per cent. No patient in either group died of thyroid carcinoma. A 2024 systematic review and meta-analysis of 21 studies and 9,397 patients found an overall progression rate during surveillance of about 14.5 per cent and a delayed-surgery rate of about 14.9 per cent, again with no thyroid-cancer mortality in either arm. That review also urged caution, noting higher overall complication and recurrence rates in patients who eventually had delayed surgery compared with those operated on immediately. Both findings matter: surveillance is safe in carefully selected patients, and careful selection is the part that does the work. The Korean Thyroid Association issued a dedicated guideline in 2025 setting out exactly which patients qualify and a follow-up schedule of neck ultrasound and thyroid function tests every six months for two years, then annually.
A question many readers now arrive with concerns GLP-1 receptor agonist medications used for type 2 diabetes and weight loss. A 2024 review in the journal Thyroid assessed the whole body of evidence and concluded that randomised trials show thyroid cancer to be a rare event with no consistent signal of increased risk, that observational studies at higher risk of bias give inconsistent results, and that pharmacovigilance reporting does show a signal but cannot establish causation. The authors note that excessive concern carries its own harms, including unnecessary screening and overdiagnosis. Anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia should raise it with their prescriber, since that specific contraindication remains.
On the genetic side, a 2026 multi-ancestry genome-wide association study of 16,167 cases and more than 2.4 million controls identified 51 independent risk loci, 21 of them not previously reported, and grouped them into clusters relating to thyroid function, DNA repair, and telomere maintenance. This is research-stage work: it points towards genetic subtypes of risk and towards future risk-stratification tools, and it does not currently change anything about how an individual is screened or treated.
Treatment for advanced disease is also moving. A search of ClinicalTrials.gov in September 2026 returns 48 recruiting phase 2 and phase 3 interventional studies in thyroid cancer. Several test redifferentiation, the strategy of using a targeted drug to restore a tumour’s ability to absorb iodine so that radioactive iodine can work again: one example is a phase 2 study of selpercatinib in RET fusion-positive, iodine-refractory disease run with the International Thyroid Oncology Group, and a companion study is examining the same approach in children and young adults with newly diagnosed RET fusion-positive tumours. These approaches are investigational, and trial participation is a decision to make with a specialist team.
Glossary
| Term | Meaning |
|---|---|
| Thyroid nodule | A lump within the thyroid gland; the large majority are benign. |
| Differentiated thyroid cancer | Papillary and follicular cancers, whose cells still behave like thyroid tissue. |
| Microcarcinoma | A papillary cancer measuring 1 centimetre or less. |
| Fine-needle aspiration | A biopsy taking cells from a nodule with a thin needle under ultrasound. |
| Bethesda category | The six-level scale used to report the result of a thyroid biopsy. |
| Lobectomy | Surgical removal of one half of the thyroid gland. |
| Thyroglobulin | A protein made by thyroid cells, followed after treatment as a disease marker. |
| Active surveillance | Planned monitoring of a low-risk cancer instead of immediate surgery. |
| Iodine-refractory | Disease that no longer takes up radioactive iodine and needs other treatment. |
Frequently asked questions
Is thyroid cancer deadly?
For most people, no. The five-year relative survival across all stages is 98.3 per cent, and more than 45,000 diagnoses in the United States in 2026 are set against roughly 2,320 expected deaths. The exception is anaplastic thyroid cancer, which accounts for about 2 per cent of cases and behaves very differently. The type matters far more than the word cancer.
What is the first sign of thyroid cancer?
Usually a painless lump in the front of the neck that moves when you swallow. Many thyroid cancers are found with no sign at all, on a scan performed for an unrelated reason. Pain is not a typical feature.
Can a blood test detect thyroid cancer?
Not on its own. Thyroid function tests measure hormone production, and most thyroid cancers do not affect it, so results are commonly normal. Calcitonin is used specifically in the assessment of medullary cancer, and thyroglobulin is used for follow-up after treatment. Ultrasound and, where indicated, a needle biopsy are what establish the diagnosis.
How fast does thyroid cancer grow?
Most papillary cancers grow very slowly, often over years, which is why monitoring is a legitimate option for small low-risk tumours. In a 30-year surveillance series, fewer than 7 per cent of monitored microcarcinomas enlarged by 3 millimetres within 20 years. Anaplastic thyroid cancer is the opposite case and can grow within weeks.
Do I need my whole thyroid removed?
Not necessarily. Current guidelines favour lobectomy, removing one lobe, for many small low-risk cancers, and monitoring without surgery for a subset of very small ones. Total thyroidectomy remains standard for larger, multifocal, or higher-risk disease. This is a decision made with a specialist, based on the size, the type, and the imaging.
Does treatment mean taking hormones for life?
After total thyroidectomy, yes, daily thyroid hormone replacement is required and is monitored with blood tests. After a lobectomy, the remaining lobe is often sufficient, and a substantial proportion of patients need no replacement at all.
Do GLP-1 medications cause thyroid cancer?
The evidence does not support that conclusion. Randomised trials show thyroid cancer occurring rarely and without a consistent increase, whilst observational data are inconsistent and reporting-based signals cannot prove causation. The established exception is a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia, which remains a reason not to use these drugs and should be discussed with the prescriber.
Sources
- Thyroid Cancer Treatment (PDQ) Patient Version — National Cancer Institute, National Institutes of Health
- Cancer Stat Facts: Thyroid Cancer — SEER Programme, National Cancer Institute
- Thyroid Cancer — MedlinePlus, National Library of Medicine
- Thyroid Cancer, Symptoms and Causes — Mayo Clinic
- Thyroid Cancer: Types, Symptoms, Causes and Treatment — Cleveland Clinic
- Ringel M.D. et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer — Thyroid, 2025 (indexed in PubMed)
- Praw S.S. et al. Executive Summary of the 2025 American Thyroid Association Management Guidelines — Thyroid, 2025 (indexed in PubMed)
- Lee E.K. et al. 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma — Endocrinology and Metabolism, 2025 (indexed in PubMed)
- Miyauchi A. et al. Long-Term Outcomes of Active Surveillance and Immediate Surgery for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma: 30-Year Experience — Thyroid, 2023
- Nguyen V.C. et al. Outcomes and effectiveness of active surveillance for low-risk papillary thyroid carcinoma: a systematic review and meta-analysis — European Archives of Oto-Rhino-Laryngology, 2024
- Espinosa De Ycaza A.E. et al. Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review — Thyroid, 2024 (indexed in PubMed)
- Jee Y.H. et al. Genetic drivers of etiologic heterogeneity in thyroid cancer — Nature Communications, 2026 (indexed in PubMed)
- Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer (NCT05668962) — ClinicalTrials.gov
- Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Differentiated Thyroid Cancers Harboring RET Fusions (NCT06458036) — ClinicalTrials.gov
Other articles
- Thyroid Nodule Blood Test: What TSH Really Decides
- TSH Blood Test: How to Read Your Thyroid Results
- Normal Thyroid Levels: How to Read Your Results
- Free T4: Easily decipher your thyroid tests
- Calcitonin Blood Test: Levels and What They Mean
- Anti-TPO Antibodies: What High Levels Mean for Your Thyroid
- Calcium Blood Test: What Your Levels Mean
- PTH Blood Test: Reading Your Results With Calcium
Thyroid results are easier to follow when each line of the report is explained in context rather than left as a number beside a range. Understand your lab results with AI DiagMe, which reads your report line by line and explains each value in plain language, with interpretation reviewed by a committee of physicians.
